SCHEMBL2066412

SCHEMBL2066412

Cc1nc[c]cc1NS(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.38
NFE2L2 Q16236 1/20 0.38
GLO1 Q04760 2/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.35
PIK3CA P42336 5/20 0.34
PIK3CD O00329 2/20 0.34
PIK3CB P42338 2/20 0.34
PIK3CG P48736 2/20 0.34
PTGS1 P23219 5/20 0.33
PTGS2 P35354 4/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
EP300 Q09472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL753334 0.80 PIK3CA (0.46) KEAP1NFE2L2GLO1ALOX15HTT
SCHEMBL752603 0.77 PIK3CD (0.41) PIK3CAPIK3CDPIK3CBPIK3CGPTGS1
SCHEMBL2068207 0.74
SCHEMBL2207940 0.69 KEAP1 (0.48) KEAP1NFE2L2GLO1ALOX15HTT
SCHEMBL4074257 0.69 GLO1 (0.64) KEAP1NFE2L2GLO1ALOX15HTT
SCHEMBL2065919 0.69 CYP3A4 (0.32)
SCHEMBL24576532 0.68 PIK3C3 (0.48) KEAP1NFE2L2GLO1ALOX15HTT
SCHEMBL21854466 0.68 CYP17A1 (0.47) KEAP1NFE2L2PIK3C3PIK3CAPIK3CD
SCHEMBL30978117 0.68 CYP17A1 (0.47) KEAP1NFE2L2PIK3C3PIK3CAPIK3CD
SCHEMBL2067700 0.66 PIK3C3 (0.36) PIK3C3HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 KEAP1 344/4885NFE2L2 2057/4885GLO1 4504/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 KEAP1 430/4885NFE2L2 2156/4885GLO1 4478/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 KEAP1 430/4885NFE2L2 2156/4885GLO1 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.